- Home
- HBCP vs BCYC Comparison
HBCP vs BCYC Comparison
Compare HBCP & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBCP | BCYC |
|---|---|---|
| Founded | 1908 | 2009 |
| Country | United States | United Kingdom |
| Employees | 481 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.8M | 476.6M |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HBCP | BCYC |
|---|---|---|
| Price | $63.14 | $7.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $63.50 | $18.73 |
| AVG Volume (30 Days) | 23.0K | ★ 241.1K |
| Earning Date | 01-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 24.56 | N/A |
| EPS | ★ 5.62 | N/A |
| Revenue | ★ $145,087,000.00 | $28,339,000.00 |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | $3.27 | N/A |
| P/E Ratio | $11.28 | ★ N/A |
| Revenue Growth | ★ 11.42 | N/A |
| 52 Week Low | $39.59 | $6.03 |
| 52 Week High | $63.67 | $13.90 |
Technical Indicators
Market Signals| Indicator | HBCP | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 65.98 | 59.18 |
| Support Level | $59.54 | $6.37 |
| Resistance Level | $62.02 | $6.88 |
| Average True Range (ATR) | 1.45 | 0.34 |
| MACD | 0.31 | 0.06 |
| Stochastic Oscillator | 82.79 | 90.38 |
Price Performance
Historical ComparisonAbout HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.